

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	10/810,020
		Filing Date	03/26/2004
		First Named Inventor	Henry C. Lin
		Art Unit	1645
		Examiner Name	
Total Number of Pages in This Submission	10	Attorney Docket Number	04-11US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Information Disclosure Statement for 37 CFR
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement Form 1449, 7 pages	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Nastech Pharmaceutical Company Inc.		
Signature			
Printed name	Paul G. Lunn		
Date	January 13, 2005	Reg. No.	32,743

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as priority mail in an priority mail box, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Jeffrey L. Granger	Date	January 13, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Henry C. Lin

U.S. Application Serial No.: 10/810,020

Filed: 3/26/2004

Title: METHODS FOR MANIPULATING  
UPPER GASTROINTESTINAL  
TRANSIT, BLOOD FLOW, AND  
SATIETY, AND FOR TREATING  
VISCERAL HYPERALGESIA

Group Art Unit: 1645

Attorney Docket No.: 04-11US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

This Information Disclosure Statement is submitted:

- ☒ under 37 CFR 1.97(b), or  
(Within three months of filing national application; or date of entry of international application; or **before mailing date of first office action** on the merits; whichever occurs last)
- ☐ under 37 CFR 1.97(c) together with either a:  
☐ Statement under 37 CFR 1.97(e), or  
☐ a \$180.00 fee under 37 CFR 1.17(p), or  
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with a:  
☐ Statement under 37 CFR 1.97(e), and  
☐ a \$180.00 fee set forth in 37 CFR 1.17(p).  
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☒ Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which

applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,



Paul G. Lunn  
Attorney/Agent for Applicant(s)  
Reg. No. 32743

Date: January 13, 2005  
Telephone No.: (425) 908-3643  
Facsimile No. (425) 908-3655


\*\*\*\*\*

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for priority mail in a box, priority mail delivery confirmation number 0103 8535 7494 8643 3866 addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Date of Deposit: January 13, 2005

Typed Name: Jeffrey L. Granger

Signature: 



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/810,020
				Filing Date	03/26/2004
				First Named Inventor	Henry C. Lin
				Art Unit	1645
Sheet	1	of	7	Examiner Name	
				Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Issued Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5,308,620	Issued 05-03-1994	Hemosphere, Inc.	
		US- 5,574,010	11-12-1996	The Regents of The University of California	
		US- 5,604,203	Issued 02-18-1997	University of Cincinnati	
		US- 5,616,311	Issued 04-01-1997	Hemosphere, Inc.	
		US- 5,696,093	Issued 12-09-1997	CRC for Biopharmaceutical Research Pty Limited	
		US- 5,716,643	Issued 02-10-1998	Hemosphere, Inc.	
		US- 5,725,804	Issued 03-10-1998	Hemosphere, Inc.	
		US- 5,759,656	Issued 06-02-1998	Novartis Corporation	
		US- 5,945,033	Issued 08-31-1999	Hemosphere, Inc.	
		US- 5,912,227	06-15-1999	North Carolina State University	
		US- 5,968,748	Issued 10-19-1999	Isis Pharmaceuticals, Inc. The Penn State Research Foundation	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP 1 288 223 A1	05.03.2003	Biomeasure Incorporated.		
		EP 1 288 224 A1	05.03.2003	Biomeasure Incorporated		
		EP 0 678 018 B1	09.04.2003	Kinerton Limited		
		EP 1 051 194 B1	14.05.2003	Kinerton Limited		
		EP 1 466 610 A1	13.10.2004	Daiichi Santory Pharma Co., Ltd.		
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/810,020	
			Filing Date	03/26/2004	
			First Named Inventor	Henry C. Lin	
			Art Unit	1645	
			Examiner Name		
Sheet	2	of	7	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Issued Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5,977,175	Issued 11-02-1999	Cedars-Sinai Medical Center	
		US- 5,980,945	Issued 11-09-1999	Societe de Conseils de Recherches et d'Applications Scientifique Recherches S.A. d'Applications Scientifique S.A.	
		US- 6,013,285	Issued 01-11-2000	Hemosphere, Inc.	
		US- 6,013,633	1-11-2000	University of Cincinnati	
		US- 6,017,879	01-25-2000	B.M.R.A. Corporation B.V.	
		US- 6,046,167	Issued 04-04-2000	University of Cincinnati	
		US- 6,191,102	Issued 02-01-2001	Eli Lilly and Company	
		US- 6,264,988	Issued 07-24-2001	Hemosphere, Inc.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		PCT WO 94/22467 A1 (International Application Number PCT/US94/03380)	10-13-1994	University of Cincinnati		
		PCT WO 98/20885 A1 (International Application Number PCT/US96/18374)	05-22-1998	University of Cincinnati		
		PCT WO 99/02135 A1 (International Application Number PCT/IT98/00192)	01.21.1999.	Sierovacciongeno italiano I.S.I. S.P.A.		
		PCT/ WO 09915516 A1 (JP)	04-01-1999	Banyu Pharm Co LTD		
Examiner Signature				Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/810,020	
			Filing Date	03/26/2004	
			First Named Inventor	Henry C. Lin	
			Art Unit	1645	
			Examiner Name		
Sheet	3	of	7	Attorney Docket Number	04-11US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Issued Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 6,391,343	Issued 05-21-2002	Hemosphere, Inc.	
		US- 6,235,718	Issued 05-22-2001	The University of Cincinnati	
		US- 6,558,708	Issued 05-06-2003	Cedars-Sinai Medical Center	
		US- 6,583,111	Issued 06-24-2003	Eli Lilly and Company	
		US- 6,737,408	Issued 05-18-2004	University of Cincinnati	
		US 2004/0228846 A1	Publication 11-18-2004	Ropes & Gray LLP	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		PCT WO 00/47219 A2 (International Application Number PCT/US00/03391)	08-17-2000	Ontogeny, Inc.		
		PCT WO 02/47712 A2 (International Application Number PCT/US01/48336)	06-20-2002	Amylin Pharmaceuticals, Inc.		
		PCT WO 03/026591 A2 (International Application Number PCT/US02/31944)	04-03-2003	Imperial College Innovations Ltd, Oregon Health and Science University		
		PCT WO 03/057235 A2 (International Application Number PCT/GB03/00062)	07-17-2003	Imperial College Innovations Ltd, Oregon Health and Science University		
		PCT WO 03/105763 A2 (International Application Number PCT/US03/18657)	12.24.2003	Amylin Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/810,020	
			Filing Date	03/26/2004	
			First Named Inventor	Henry C. Lin	
			Art Unit	1645	
			Examiner Name		
Sheet	4	of	7	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MEI-HUEI CHEN; BALASUBRAMANIAN; MURPHY; TABATA; FISCHER; CHEN; JOFFE, Sensitive Radioimmunoassay for Measurement of Circulating Peptide YY, Gastroenterology, 1984, Pages 1332-1338, Volume 87, Publisher: American Gastroenterological Association, Published in: Cincinnati, Ohio	
		MORLEY, JOHN E.; LEVINE, ALLEN S.; GRACE, MARTHA; KNEIP, JULIE, "Peptide YY (PYY), a potent orexigenic agent," Brain Research, 1985, Vol. 341, Pages 200-203. Elsevier Science Publishers.	
		JOHN E. MORLEY AND JAMES F. FLOOD, An Investigation of Tolerance to the actions of Leptogenic and Anorexigenic Drugs in Mice, Life Sciences, 9/10/1987, Page(s) 22157-2165, Volume 41, Publisher: Pergamon Journals, Published in: Sepulveda, CA, US	
		KAZUHIKO TATEMOTO; NAKANO; MAKI; ANGWIN; MANN; SCHILLING; GO, Isolation and Primary Structure of Human Peptide YY, Biochemical and Biophysical Research Communications, 10/31/1988, Pages 713-717, Volume 157(2), Publisher: Academic Press, Inc., Published in: Los Angeles, California, US	
		BALASUBRAMANIAM, A.; SERVIN, A. L.; RIGEL, D. F.; ROUYER-FESSARD, C. R.; LABURTHE, M., Syntheses and receptor affinities of partial sequences of peptide YY (PYY) Peptide Research., date- 1988, volume 1, No. 1, pages 32-35	
		JOHN E. MORLEY, An approach to the development of drugs for appetite disorders, Neuropsychobiology, Date 1989, Volume 21, issue 1, pages 22-30, Karger AG, Basel	
		EBERLEIN, G. A.; EYSSELEIN, V. E.; SCHAEFFER, M.; LAYER, P.; GRANDT, D.; GOEBELL, H.; NIEBEL, W.; DAVIS, M.; LEE, T. D.; SHIVELY, J. E.; REEVE, J. R., JR.; A new molecular form of PYY: structural characterization of human PYY(3-36) and PYY(1-36) Peptides, DATE- 1989, Vol 10, No. 4, pages 797-803, Pergamon Press, US	
		EYSSELEIN, V. E.; EBERLEIN, G. A.; GRANDT, D.; SCHAEFFER, M.; ZEHRES, B.; BEHN, U.; SCHAEFER, D.; GOEBELL, H.; DAVIS, M.; LEE, T. D.; SHIVELY, J. E.; MEYER, H. E.; REEVE, J. R., JR, Structural characterization of canine PYY, Peptides, 06/15/1989, Vol. 11 Pages 111-116, Pergamon Press, US	
		HIROYUKI MINAKATA, TAKASHI IWASHITA, Synthesis of analogues of peptide YY with modified N-terminal regions: relationships of amphiphilic secondary structures and activity in rat vas deferens, Journal: Biopolymers, Vol 29, 1/29/1990, pages 61-67, John Wiley & Sons, Inc.	
		RAMO, O. J.; BALASUBRAMANIAM, A.; SHERIFF, S.; ROGERS, D. H.; MCCULLOUGH, P. J.; BELL, R. H., JR., Neuropeptide Y and peptide YY stimulate the growth of exocrine pancreatic carcinoma cells, Neuropeptides, 1990, vol 15, pages 101-106, Longman Group UK	
		S.F. LEIBOWITZ, J.T. ALEXANDER, Analysis of Neuropeptide Y-Induced Feeding: Dissociation of Y1 and Y2 Receptor Effects on Natural Meal Patterns, Peptides, 7/25/1991, Pages 1251-1260, Volume 12, Publisher: Pergamon Press, Published in: New York NY, US	
		MARC LABURTHE, Peptide YY et neuropeptide Y dans L'intestin: disponibilite, effets biologiques et recepteurs epitheliaux, [translated title: Peptide YY and neuropeptide Y in the intestine: availability, biologic effects and epithelial receptors] Arch Int. Physiol Biochim Biophys, Reunion Complementaire de Physiologie, Association des Physiologistes, Toulouse 26-27, 04/1991, France.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/810,020
				Filing Date	03/26/2004
				First Named Inventor	Henry C. Lin
				Art Unit	1645
				Examiner Name	
Sheet	5	of	7	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		INUI AKIO, MINORU OKITA, MASAHARU NAKAJIMA, TORU INOUE, NORIAKI SAKATANI, MANABU OYA, HIDEKI MORIOKA, YASUHIKO OKIMURA, KAZUO CHIHARA, AND SHIGEAKI BABA, Neuropeptide regulation of feeding in dogs, Neuropeptides and Food Intake, 1991, Pages R5888-R594, 0363-6119, The American Physiological Society	
		GRANDT, D.; TEYSSEN, S.; SCHIMICZEK, M.; REEVE, J. R., JR.; FETH, F.; RASCHER, W.; HIRCHE, H.; SINGER, M. V.; LAYER, P.; GOEBELL, H.; HO, F. J.; EYSSELEIN, V. E.: Novel generation of hormone receptor specificity by amino terminal processing of peptide YY, Biochemical and Biophysical Research Communications, 08/14/1992, volume 186, no. 3, pages 1299-1306, Academic Press, Inc.	
		S. OKADA, OHSHIMA, MORI, K. TATEMOTO, Peripherally not Centrally Administered Peptide YY(PYY) Decreases High Fat Diet Intake, 6/9/1993, Volume 520, Publisher: Endocrinology, Published in: Gunmo, Japan	
		GRANDT, D.; SCHIMICZEK, M.; STRUK, K.; SHIVELY, J.; EYSSELEIN, V. E.; GOEBELL, H.; REEVE, J. R., JR - Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit, Peptides, 07/29/1994, Volume 15, no 5, pages 815-820, Pergamon, Elsevier Science Ltd, US	
		DUMONT, YVAN.; CADIEUX, ALAIN.; PHENG, L. H.; FOURNIER, A.; ST PIERRE, S.; QUIRION, R., Peptide YY derivatives as selective neuropeptide Y/peptide YY Y <sup>1</sup> and Y <sup>2</sup> agonists devoided of activity for the Y <sub>3</sub> receptor sub-type, Brain Research.Molecular.Brain Research, - 06/28/1994, Vol 26, no 1-2, pages 320-324, Elsevier Science B.V.	
		WLODARCZYK-BISAGA K.; BISAGA A., Biologiczne aspekty zaburzeń odżywiania się – wybrane zagadnienia [Selected issues of biological aspects of eating disorders], Psychiatria Polska, 1994 Sep-Oct, vol. 28, no. 5: pages 579-591. Poland.	
		MARGARET DOS SANTOS MEDEIROS, M. D.; ANTHONY J. TURNER, Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11, Endocrinology 1994, Vo 134, No. 5, pages 2088-2094, The Endocrine Society, US	
		GRANDT, D.; SCHIMICZEK, M.; BEGLINGER, C.; LAYER, P.; GOEBELL, H.; EYSSELEIN, V. E.; REEVE, J. R., JR, Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36, Regulatory Peptides, 5-5-1994, Vol 51, No. 2, Pages 151-159, Elsevier Sciences B.V.	
		KAZUHIKO TATEMONO, New Developments in Research on digestive tract hormones, Progress in Medicine, Vol 15, No. 9, date 09/1995, pages 1793-1804, 46 <sup>th</sup> Pepsin Research Meeting (translated from Japanese) JP	
		NORIO TANI, Digestive Tract Hormones, Digestive Tract, 1996, Article Serial No.: 0012 (translated from Japanese) JP	
		GUE, M.; JUNIEN, J. L.; REEVE, J. R., JR.; RIVIER, J.; GRANDT, D.; TACHE, Y, Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats, British Journal of Pharmacology, 05/1996, pages 118(2), 237-242, Stockton Press	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/810,020
				Filing Date	03/26/2004
				First Named Inventor	Henry C. Lin
				Art Unit	1645
Sheet	6	of	7	Examiner Name	
				Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite <sup>1</sup> No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		VON E. NIEBERGALL-ROTH, S. TEYSSEN K. RIPPEL UND M.V. SINGER, Die wirkungen von peptide yy auf funktionen des gastrointestinaltraktes, Dtsch. Tierarztl. Wschr 104, pages 85-124, Heft 3, Marz 1997, National Library of Medicine (article in German)	
		KAZUHIKO TATEMOTO, Chemical and clinical Applications of Digestive Tract hormones, Digestive Tract hormones, 1994, pages 38-45, Vol. 2, no. 4, G. I. Research (translated Japanese article) JP	
		CHEN, C. H.; STEPHENS, R. L., JR.; ROGERS, R. C., PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC, Neurogastroenterol.Motil. 1997, pages 109-116, volume 9, Blackwell Science Ltd., US	
		XIAO, Q.; HAN, X.; ARANY, E.; HILL, D.; CHALLIS, J. R.; MCDONALD, T. J., Human placenta and fetal membranes contain peptide YY1-36 and peptide YY3-36, Journal of Endocrinology, 1998, pages 485-492, Vol 156, Journal of Endocrinology Ltd, UK	
		NARUTO YAMAWAKI, YASUAKI OKAMOTO, Is there a biological case for eating disorders? From the perspective of neurochemistry, Brian Science, 1998, pages 29-36, Article Serial Number 0003, volume 20, Special Edition (Eating Disorders and Obesity) Think also presented at conference 04/24/1998 at Showa University, Yokohama, Japan (translated Japanese article) JP	
		NOBORU YANAIHARA, VIP, PYY and Others, All About Hormone Illustrated No. 381, 1998, page 382-387, Article Serial Number 0033, volume 46, VI. Gastrointestinal Hormones, (translated Japanese article) JP	
		KAZUHIKO TATEMOTO, Development of Neuropeptide Y Receptor Antagonists, Research on Biologically Active Substances, Research Papers of the Suzuken Memorial Foundation, Vol. 14, page 243-244 (translated Japanese article) JP	
		DAVID A. KEIRE, MITSUO KOBAYASHI, TRAVIS E. SOLOMON, JOSEPH R. REEVE, JR., Solution structure of monomeric peptide YY supports the functional significance of the PP-Fold, Biochemistry 2000, pages 9935-9942, 11/8/1999, American Chemical Society, published on web 07/21/2000, US	
		PHILIPPE NAVEILHAN, HESSAMEH HASSANI, JOSEP M. CANALS, A. JONAS EKSTRAND, ASA LAREFALK, VIJAY CHHAJLANI, ERNEST ARENAS, KARIN GEDDA, LENNART SVENSSON, PETER THOREN, AND PATRIK ERNFORS, Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor, Nature America Inc. 10/1999, pages 1188-1193, volume 5, number 10, Nature Medicine	
		AKIHIRO ASAKAWA, AKIO INUI, NAOHIKO UENO, MINEKO FUJIMIYA, MASAYUKI A. FUJINO, MASATO KASUGA, Mouse pancreatic polypeptide modulated food intake, while not influencing anxiety in mice, Peptides, 1999, pages 1445-1448, Volume 20, Elsevier Science Inc.	
		KEIRE, D. A.; MANNON, P.; KOBAYASHI, M.; WALSH, J. H.; SOLOMON, T. E.; REEVE, J. R., JR., Primary structures of PYY, [Pro <sup>36</sup> ]PYY, and PYY-(3-36) confer different conformations and receptor selectivity, Am.J.Physiol Gastrointest.Liver Physiol, 2/1/2000, page G126-G131, Volume 279	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/810,020
				Filing Date	03/26/2004
				First Named Inventor	Henry C. Lin
				Art Unit	1645
				Examiner Name	
Sheet	7	of	7	Attorney Docket Number	04-11US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		RACHEL L. BATTERHAM, MICHAEL A. COWLEY, CAROLINE S. SMALL, HERBERT HERZOG, MARK A. COHEN, CATHERINE L. DAKIN, ALISON M. WREN, AUDREY E. BRYNES, MALCOM J. LOW, MOHAMMAD A. GHATEI, ROGER D. CONE, STEPHEN R. BLOOM. "Gut hormone PYY3-36 physiologically inhibits food intake," Nature, 2002, Vol. 418, Pages 650-654, Nature Publishing Group.	
		HERBERT HERZOG, Hypothalamic Y2 Receptors: Central Coordination of Energy Homeostasis and Bone Mass Regulation, Drug News Perspect. 10/2002, pages 506-510, Volume 15 (8), Prous Science	
		BATTERHAM, RACHEL. L.; COHEN, MARK. A.; ELLIS, SANDRA. M.; LE ROUX, CAREL. W.; WITHERS, DOMINIC. J.; FROST, GARY. S.; GHATEI, M. A.; BLOOM, S. R., Inhibition of food intake in obese subjects by peptide YY3-36, The New England Journal of Medicine, DATE- 9-4-2003, pages 941-948, vol 349,	
		RACHEL L. BATTERHAM, STEPHEN R. BLOOM, The gut hormone peptide YY regulates appetite, N.Y. Academy of Sciences, 2003, pages 162-168, volume 994,	
		R. L. BATTERHAM, C.W. LE ROUX, M.A. CHOEN, A.J. PARK, S.M. ELLIS, M. PATTERSON, G.S. FROST, M.A. GHATEI AND S.R. BLOOM, Pancreatic polypeptide reduces appetite and food intake in humans, The Journal of Clinical Endocrinology and Metabolism, 2003, pages 3989-3992, vol 88(8), the Endocrine Society, US	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.